Supporting Information

A novel fluorescence-electrochemiluminescence dual-mode sensing platform for high-precision BRAF gene detection

Fengyao Yu\textsuperscript{a, \#}, Longyue Qin\textsuperscript{b, \#}, Hua Zhang\textsuperscript{a, *}, Longshua Qin\textsuperscript{a, *}, Hao Fan\textsuperscript{a, *}

\textsuperscript{a} Department of Pharmacy, JiangXi University of Chinese Medicine, Nanchang, JiangXi 330004, China
\textsuperscript{b} School of Materials Science and Engineering, Kunming University of Science and Technology, Kunming, YunNan 650031, China

\# Fengyao Yu and Longyue Qin contributed equally to this paper.

*Corresponding Author:

E-mail addresses: 2327476065@qq.com (Hua Zhang)
E-mail addresses: qinlongshua@163.com (Longshua Qin)
E-mail addresses: fanhao11@aliyun.com (Hao Fan)
1. The synthesis of 2,5-dioxopyrrolidin-1-yl 3,5-bis((3,5-bisferrocenethoxybenzyl)oxy)benzoate.

Scheme S1. The synthesis of 2,5-dioxopyrrolidin-1-yl 3,5-bis((3,5-bisferrocenethoxybenzyl)oxy)benzoate (10).

Procedures for the synthesis of 2,5-dioxopyrrolidin-1-yl 3,5-bis((3,5-bisferrocenethoxybenzyl)oxy)benzoate (10):

**α-chloroacetylferrrocene (2).**
To a solution of ferrocene (11.2 g, 60 mmol) in dichloromethane (60 mL) at 0 °C, a solution of chloracetyl chloride (3.8 mL, 50 mmol) and anhydrous aluminum trichloride
(6.6 g, 50 mmol) in dichloromethane (80 mL) was added dropwise. After stirred for 8 h at room temperature, brine (100 mL) was added. The organic phase was separated and washed by brine. The resulting solution was dried over anhydrous Na₂SO₄, filtered and concentrated in vacuum. The residue was purified by flash column chromatography to give orange crystal in 41.5% yield. ¹H NMR (CDCl₃, 600MHz): δ 4.88 (Cp-H, t, J = 2.0 Hz, 2 H), 4.62 (Cp-H, t, J = 2.0 Hz, 2 H), 4.46 (CH₂, s, 2 H), 4.25 (Cp-H, s, 5 H).

2-Chloroethylferrocene (3).

A solution of α-chloroacetylferrocene (1.2 g, 4.58 mmol) in Et₂O (120 mL) was added dropwise to a solution of LiAlH₄ (180 mg, 4.7 mmol) and AlCl₃ (609 mg, 4.58 mmol) in Et₂O (90 mL) at -10 °C. After 1 h, the reaction was carefully quenched by addition of H₂O (20 mL) and diluted with brine (100 mL). The aqueous layer was extracted with ethyl acetate (3×50 mL). The combined organic layer was washed with brine (3×50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by flash column chromatography to give yellow product (3) (0.76 g, 67%). ¹H NMR (CDCl₃, 600 MHz) δ 4.16 (Cp-H, s, 7H), 4.13 (Cp-H, s, 2H), 3.62 (CH₂-O, t, J = 7.2 Hz, 2H), 2.84 (Fc-CH₂-, t, J = 7.2 Hz, 2H).

Methyl 3,5-bisferrocenethoxybenzoate (5).

2-Chloroethylferrocene (548.1 mg, 2.21 mmol), methyl 3,5-dihydroxybenzoate (154.6 mg, 0.92 mmol), anhydrous potassium carbonate (552 mg, 4 mmol) and potassium iodide (10 mg, 0.06 mmol) in DMF (4 mL) was mixed together and stirred at 80 °C until disappearance of starting material was observed by TLC. The mixture was diluted with ethyl acetate (80 mL) and washed with water (3×30 mL) and brine (3×30 mL). The organic phase was dried over anhydrous sodium sulfate and the solvent was removed in vacuum. The residue was purified by a silica gel column with ethyl acetate-petroleum ether as the eluent to give (5) as yellow solid (398 mg, 73%). ¹H NMR (CDCl₃, 600 MHz) δ 7.19 (Ar-H, s, 1H), 7.11 (Ar-H, d, J = 2.4 Hz, 2H), 4.09 (Cp-H, t, J = 1.5 Hz, 4H), 4.06 (Cp-H, s, 10H), 4.04-4.02 (Cp-H, -CH₂-O, m, 8H), 3.82 (O-CH₃, s, 3H), 2.75 (Fc-CH₂-, t, J = 7.2 Hz, 4H). ¹³C NMR (CDCl₃, 150 MHz) δ 166.9, 159.9, 131.9, 107.7, 106.8, 84.6, 68.8, 68.6, 68.6, 67.5, 52.3, 29.5. HRMS (ESI) Calcd. for C₃₂H₃₂Fe₂O₄ [M⁺]: 592.0999; found 592.0991.

(3, 5-bisferrocenethoxyphenyl)methanol (6).

To a solution of LiAlH₄ (28.8 mg, 0.76 mmol) in anhydrous ether (10 mL), a solution of methyl 3, 5-bisferrocenethoxy-benzoate (50 mg, 0.084 mmol) in anhydrous ether (15 mL) was added dropwise at 0 °C. The mixture was stirred at room temperature until the disappearance of the starting material. And then the reaction was carefully quenched by H₂O (20 mL), the aqueous layer was separated and extracted with diethyl ether (3×25 mL). The combined organic layer was washed with brine (3×50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by flash column chromatography to give orange crystal (6). Yields: 89.0%. ¹H NMR (CDCl₃, 600 MHz)
δ 6.55 (Ar-H, s, 2H), 6.43 (Ar-H, s, 1H), 4.64 (ArCH2-O, s, 2H), 4.20-4.13 (Cp-H, m, 18H), 4.10 (-CH2-O, t, J = 7.2 Hz, 4H), 2.84 (Fc-CH2-, t, J = 7.2 Hz, 4H). HRMS (ESI) Calcd. for C31H32Fe2O3 [M]+: 564.1050; found 564.1037.

3, 5-bisferrocenethoxybenzyl chloride (7).

To a solution of PPh3 (0.4313 g, 1.65 mmol) in CCl4 (10 mL), a solution of (3, 5-bisferrocenethoxyphenyl)methanol (0.7739 g, 1.37 mmol) in CH2Cl2 (10 mL) was added dropwise. The mixture solution was refluxed for 30 min and observed by TLC. The mixture was diluted with dichloromethane (40 mL) and washed with water (3×20 mL) and brine (3×20 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated. The residue was purified by a silica gel column with ethyl acetate-petroleum ether as the eluent to gave (7) as dark orange solid. 1H NMR (CDCl3, 600 MHz) δ 6.55 (Ar-H, d, J = 1.8 Hz, 2H), 6.43 (Ar-H, t, J = 2.4 Hz, 1H), 4.53 (ArCH2-O, s, 2H), 4.18 (Cp-H, t, J = 1.8 Hz, 4H), 4.15 (Cp-H, s, 10H), 4.11 (Cp-H, t, J = 1.8 Hz, 4H), 4.09 (-CH2-O, t, J = 7.2 Hz, 4H), 2.83 (Fc-CH2-, t, J = 7.2 Hz, 4H). 13C NMR (CDCl3, 150 MHz) δ 160.3, 139.5, 107.1, 101.3, 84.6, 68.7, 68.6, 68.6, 67.5, 46.2, 29.2. HRMS (ESI) Calcd. for C31H31ClFe2O3 [M]+: 582.0711; found 582.0731.

Methyl 3, 5-bis(3, 5-bisferrocenethoxybenzyloxy)benzoate (8).

To a solution of methyl 3,5-dihydroxybenzoate (6.6 mg, 0.039 mmol) and anhydrous K2CO3 (21.5 mg, 0.156 mmol) in 10 mL of DMF, 3, 5-bisferrocenethoxybenzyl chloride (50 mg, 0.085 mmol) was added. The reaction was stirred at 80 °C under nitrogen atmosphere and observed by TLC. The mixture was diluted with ethyl acetate (30 mL) and washed with brine (3×15 mL). The organic phase was dried over anhydrous sodium sulfate and the solvent was removed in vacuum. The residue was purified by a silica gel column with ethyl acetate-petroleum ether as the eluent to gave (8) as dark yellow solid. 1H NMR (CDCl3, 600 MHz) δ 7.30 (Ar-H, d, J = 2.4 Hz, 2H), 6.82 (Ar-H, t, J = 2.4 Hz, 1H), 6.59 (Ar-H, d, J = 2.4 Hz, 4H), 6.45 (Ar-H, t, J = 2.4 Hz, 2H), 5.01 (ArCH2-O, s, 4H), 4.18 (Cp-H, t, J = 1.2 Hz, 8H), 4.15-4.09 (Cp-H and -CH2-O, m, 36H), 3.91 (-COOCH3, s, 3H), 2.83 (Fc-CH2-, t, J = 7.2 Hz, 8H).

3, 5-bisferrocenethoxybenzyloxybenzoic acid (9).

To a solution of methyl 3,5-bis(3, 5-bisferrocenethoxybenzyloxy)benzoate (50 mg, 0.04 mmol) in THF/MeOH (10 mL, v/v=1:1), 10% aqueous sodium hydroxide (2 mL) was added at room temperature. The mixture was kept stirring overnight, the pH was adjusted to about 5 with dilute hydrochloric acid. The resulting orange crystals were collected by filtration, washed with water, and dried under vacuum. A pure sample was obtained by recrystallization from dichloromethane/petroleum ether to give (9) (32 mg, 65% yield, purity > 95%) as dark yellow solid. 1H NMR (CDCl3, 600 MHz) δ 7.32 (Ar-H, s, 2H), 6.85 (Ar-H, s, 1H), 6.59 (Ar-H, s, 4H), 6.44 (Ar-H, s, 2H), 5.01 (ArCH2-O, s, 4H), 4.20-4.11 (Cp-H, m, 36H), 4.09 (-CH2-O, t, J = 7.2 Hz, 8H), 2.83 (Fc-CH2-, t, J = 6.6 Hz, 8H). HRMS (ESI) Calcd. for C69H66Fe2O8 [M]+: 1246.2155; found 1246.2091.
2,5-dioxopyrrolidin-1-yl 3,5-bis((3,5-bisferrocenethoxybenzyl)oxy)benzoate (10). To a solution of 3, 5-bis(3, 5-bisferrocenethoxybenzyl)oxy)benzoic acid (24.22 mg, 1.96 mmol) in DMF (3 mL), NHS (0.361 g, 3.14 mmol) and EDC (0.601 g, 3.14 mmol) was added at 0°C. The mixture was diluted with H₂O (40 mL) and extracted with CH₂Cl₂ (3×25 mL) after kept stirring overnight at room temperature. The organic phase was filtered and dried in vacuum to obtain (10) as light yellow solid. 1H NMR (CDCl₃, 400 MHz) δ 8.02 (Ar-H, s, 1H), 7.35 (Ar-H, s, 1H), 6.88 (Ar-H, s, 1H), 6.56 (Ar-H, s, 4H), 6.42 (Ar-H, s, 2H), 4.99 (ArCH₂-O, s, 4H), 4.08-4.16 (Cp-H, m, 36H), 4.08 (-CH₂-O, t, J = 8 Hz, 8H), 2.96 (CO-CH₂-CH₂-CO, s, 4H), 2.83 (Fc-CH₂, t, J = 6.6 Hz, 8H).

1H NMR of methyl 3,5-bisferrocenethoxybenzoate (5)

13C NMR of methyl 3,5-bisferrocenethoxybenzoate (5)
HRMS of methyl 3,5-bisferrocenethoxybenzoate (5)

$^1$H NMR of (3, 5-bisferrocenethoxyphenyl)methanol (6)

HRMS of (3, 5-bisferrocenethoxyphenyl)methanol (6)
$^1$H NMR of 3, 5-bisferrocenethoxybenzyl chloride (7)

$^{13}$C NMR of 3, 5-bisferrocenethoxybenzyl chloride (7)
HRMS of 3, 5-bisferrocenethoxybenzyl chloride (7)

$^1$H NMR of methyl 3, 5-bis(3, 5-bisferrocenethoxybenzyloxy)benzoate (8)
$^1$H NMR of 3, 5-bis(3, 5-bisferrocenethoxybenzyloxy)benzoic acid (9)

HRMS of 3, 5-bis(3, 5-bisferrocenethoxybenzyloxy)benzoic acid (9)
**Fig. S1.** FL (A) and ECL (B) intensity synthesized with different ratios of Ru(debpy)$_3^{2+}$ and debpy.

**Fig. S2.** X-ray Diffraction (XRD) plots of RuMOFNCs.

**Fig. S3.** The EDS spectrometer of RuMOFNCs@AuNPs, element mapping of C, N, O, Ru, Ni, Au, and sum spectrum.
Fig. S4. AuNPs are modified to enhance the FL and ECL of RuMOFNCs based on the surface plasmon resonance effect.

Fig. S5. FL and ECL quenching efficiency of RuMOFNCs by ferrocene and tetraferrocene.

Fig. S6. Optimization of experimental conditions. pH of PBS (A), EXO III digestion time (B) and EXO III digestion temperature (C). Error bars = RSD (n = 6).
Fig. S7. The intensity comparison of ECL (A) and FL (B) of RuMOFNCs and Ru(dcbpy)$_2^{2+}$.

Fig. S8. The ECL spectra (A) and UV absorption spectra (B) of RuMOFNCs and Ru(dcbpy)$_2^{2+}$. UV absorption spectrum of Tetraferrocence (C).

Fig. S9. Optimization of P-DNA modification in FL (A) and ECL sensing modes (B).
Table S1. Comparison of the various methods for detecting BRAF gene.

<table>
<thead>
<tr>
<th>Method</th>
<th>Linear range</th>
<th>Detection Limit</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>FL-ECL</td>
<td>0.1 fM~1 nM</td>
<td>10.3 aM</td>
<td>This work</td>
</tr>
<tr>
<td>FL</td>
<td>0.01 fM~10 pM</td>
<td>3.1 aM</td>
<td>1</td>
</tr>
<tr>
<td>ECL</td>
<td>200 zM~2 pM</td>
<td>200 zM</td>
<td>2</td>
</tr>
<tr>
<td>ECL</td>
<td>1 pM~1 nM</td>
<td>3.06 fM</td>
<td>3</td>
</tr>
<tr>
<td>SPR-ECL</td>
<td>0.5 pM~2000 pM</td>
<td>0.34 pM</td>
<td>4</td>
</tr>
<tr>
<td>RCA-FRET</td>
<td>75 fM~4.5 pM</td>
<td>60 ± 10 pM</td>
<td>5</td>
</tr>
<tr>
<td>ECL</td>
<td>1 pM~1.5 nM</td>
<td>0.3 pM</td>
<td></td>
</tr>
</tbody>
</table>

Table S2. Recovery tests for BRAF gene in human serum samples.

<table>
<thead>
<tr>
<th>sample</th>
<th>Added(fM)</th>
<th>Measured (fM)</th>
<th>Recovery (%)</th>
<th>RSD (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.1</td>
<td>5</td>
<td>FL 4.92 ECL 4.98</td>
<td>98.40</td>
<td>99.60</td>
</tr>
<tr>
<td>No.2</td>
<td>10</td>
<td>FL 10.12 ECL 10.21</td>
<td>101.2</td>
<td>102.10</td>
</tr>
<tr>
<td>No.3</td>
<td>20</td>
<td>FL 20.50 ECL 20.61</td>
<td>102.5</td>
<td>103.05</td>
</tr>
</tbody>
</table>

Reference